RS58951B1 - Lečenje multiple skleroze - Google Patents
Lečenje multiple sklerozeInfo
- Publication number
- RS58951B1 RS58951B1 RS20190786A RSP20190786A RS58951B1 RS 58951 B1 RS58951 B1 RS 58951B1 RS 20190786 A RS20190786 A RS 20190786A RS P20190786 A RSP20190786 A RS P20190786A RS 58951 B1 RS58951 B1 RS 58951B1
- Authority
- RS
- Serbia
- Prior art keywords
- multiple sclerosis
- sclerosis treatment
- treatment
- sclerosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2016/063368 WO2016198649A1 (en) | 2015-06-12 | 2016-06-10 | Biomarkers associated with lsd1 inhibitors and uses thereof |
PCT/EP2017/064206 WO2017212061A1 (en) | 2015-06-12 | 2017-06-09 | Method of treating multiple sclerosis employing a lsd1-inhibitor |
EP17735004.8A EP3307267B1 (en) | 2016-06-10 | 2017-06-09 | Multiple sclerosis treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
RS58951B1 true RS58951B1 (sr) | 2019-08-30 |
Family
ID=59276685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20190786A RS58951B1 (sr) | 2016-06-10 | 2017-06-09 | Lečenje multiple skleroze |
Country Status (8)
Country | Link |
---|---|
US (1) | US10780081B2 (sr) |
EP (1) | EP3307267B1 (sr) |
CA (1) | CA2988220C (sr) |
ES (1) | ES2732669T3 (sr) |
PL (1) | PL3307267T3 (sr) |
RS (1) | RS58951B1 (sr) |
SG (1) | SG11201710199PA (sr) |
SI (1) | SI3307267T1 (sr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201913290QA (en) | 2016-03-15 | 2020-03-30 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for the treatment of hematological malignancies |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
AU2005322312B2 (en) | 2004-12-16 | 2011-05-26 | President And Fellows Of Harvard College | Histone demethylation mediated by the nuclear amine oxidase homolog LSD1 |
ATE476970T1 (de) | 2005-02-18 | 2010-08-15 | Universitaetsklinikum Freiburg | Kontrolle der androgen rezeptor-abhängigen gen expression durch hemmung der aminoxidase aktivität der lysin spezifischen demethylase (lsd1) |
RU2008108632A (ru) | 2005-08-10 | 2009-09-20 | Джонс Хопкинс Юниверсити (Us) | Полиамины, используемые при противопаразитарных и противораковых терапиях и в качестве ингибиторов лизин-специфической деметилазы |
WO2008127734A2 (en) | 2007-04-13 | 2008-10-23 | The Johns Hopkins University | Lysine-specific demethylase inhibitors |
US8916596B2 (en) | 2008-07-24 | 2014-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Preventing or treating viral infection using an inhibitor of the LSD1 protein, a MAO inhibitor or an inhibitor of LSD1 and a MAO inhibitor |
EP2361242B1 (en) | 2008-10-17 | 2018-08-01 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
EP2389362B1 (en) | 2009-01-21 | 2019-12-11 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
US8389580B2 (en) | 2009-06-02 | 2013-03-05 | Duke University | Arylcyclopropylamines and methods of use |
EP2258865A1 (en) | 2009-06-05 | 2010-12-08 | Universitätsklinikum Freiburg | Lysine-specific demethylase 1 (LSD1) is a biomarker for breast cancer |
WO2010143582A1 (ja) | 2009-06-11 | 2010-12-16 | 公立大学法人名古屋市立大学 | フェニルシクロプロピルアミン誘導体及びlsd1阻害剤 |
EP2467359A4 (en) | 2009-08-18 | 2013-01-09 | Univ Johns Hopkins | (BIS-) UREA- AND (BIS-) THIOMINE COMPOUNDS AS EPIGENE MODULATORS OF THE LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF DISEASE TREATMENT THEREWITH |
BR112012006572A2 (pt) | 2009-09-25 | 2016-04-26 | Oryzon Genomics Sa | inibidores de demetilase-1 de lisina específicos e seu uso |
US8946296B2 (en) | 2009-10-09 | 2015-02-03 | Oryzon Genomics S.A. | Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use |
US9186337B2 (en) | 2010-02-24 | 2015-11-17 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae |
WO2011106574A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Inhibitors for antiviral use |
WO2011113005A2 (en) | 2010-03-12 | 2011-09-15 | The Johns Hopkins University | Compositions and methods for combinations of oligoamines with 2-difluoromethylornithine (dfmo) |
WO2011131697A1 (en) | 2010-04-19 | 2011-10-27 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
WO2011131576A1 (en) | 2010-04-20 | 2011-10-27 | Università Degli Studi Di Roma "La Sapienza" | Tranylcypromine derivatives as inhibitors of histone demethylase lsd1 and/or lsd2 |
US9006449B2 (en) | 2010-07-29 | 2015-04-14 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as LSD1 inhibitors |
EP3375775A1 (en) | 2010-07-29 | 2018-09-19 | Oryzon Genomics, S.A. | Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use |
WO2012034116A2 (en) | 2010-09-10 | 2012-03-15 | The Johns Hopkins University | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders |
US20130303545A1 (en) | 2010-09-30 | 2013-11-14 | Tamara Maes | Cyclopropylamine derivatives useful as lsd1 inhibitors |
WO2012045883A1 (en) | 2010-10-08 | 2012-04-12 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
WO2012107498A1 (en) | 2011-02-08 | 2012-08-16 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
US20140163041A1 (en) | 2011-02-08 | 2014-06-12 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders |
CN103857393B (zh) | 2011-03-25 | 2016-08-17 | 葛兰素史密斯克莱知识产权(第2号)有限公司 | 环丙基胺作为lsd1抑制剂 |
WO2012156537A2 (en) | 2011-05-19 | 2012-11-22 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for thrombosis and cardiovascular diseases |
WO2012156531A2 (en) | 2011-05-19 | 2012-11-22 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for inflammatory diseases or conditions |
EP2768805B1 (en) | 2011-10-20 | 2020-03-25 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
BR112014009238B1 (pt) | 2011-10-20 | 2022-08-09 | Oryzon Genomics S.A. | Compostos de (hetero)aril ciclopropilamina, seus usos e composições farmacêuticas |
EP3090998A1 (en) | 2015-05-06 | 2016-11-09 | F. Hoffmann-La Roche AG | Solid forms |
KR20180011331A (ko) | 2015-06-12 | 2018-01-31 | 오리존 지노믹스 에스.에이. | Lsd1 억제제와 관련된 바이오마커 및 그의 용도 |
WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
EP3359684A1 (en) | 2015-10-09 | 2018-08-15 | Oryzon Genomics, S.A. | Gene expression biomarkers for personalized cancer care to epigenetic modifying agents |
SG10201913290QA (en) | 2016-03-15 | 2020-03-30 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for the treatment of hematological malignancies |
MX2018011102A (es) | 2016-03-15 | 2019-01-10 | Oryzon Genomics Sa | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. |
JP2019512546A (ja) | 2016-03-16 | 2019-05-16 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Kdm1a標的会合を決定するための方法、およびそれに有用な化学プローブ |
WO2018083138A1 (en) | 2016-11-03 | 2018-05-11 | Oryzon Genomics, S.A. | Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents |
EP3535420A1 (en) | 2016-11-03 | 2019-09-11 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
-
2017
- 2017-06-09 RS RS20190786A patent/RS58951B1/sr unknown
- 2017-06-09 US US15/741,871 patent/US10780081B2/en active Active
- 2017-06-09 SI SI201730061T patent/SI3307267T1/sl unknown
- 2017-06-09 ES ES17735004T patent/ES2732669T3/es active Active
- 2017-06-09 PL PL17735004T patent/PL3307267T3/pl unknown
- 2017-06-09 EP EP17735004.8A patent/EP3307267B1/en active Active
- 2017-06-09 CA CA2988220A patent/CA2988220C/en active Active
- 2017-06-09 SG SG11201710199PA patent/SG11201710199PA/en unknown
Also Published As
Publication number | Publication date |
---|---|
SG11201710199PA (en) | 2018-05-30 |
US10780081B2 (en) | 2020-09-22 |
EP3307267A1 (en) | 2018-04-18 |
ES2732669T3 (es) | 2019-11-25 |
US20190083469A1 (en) | 2019-03-21 |
CA2988220A1 (en) | 2017-12-10 |
SI3307267T1 (sl) | 2019-08-30 |
CA2988220C (en) | 2021-03-02 |
EP3307267B1 (en) | 2019-04-10 |
PL3307267T3 (pl) | 2019-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1244686A1 (zh) | 胰腺炎治療 | |
IL269371A (en) | Treatment methods | |
HK1252645A1 (zh) | 按摩機 | |
LT3307267T (lt) | Išsėtinės sklerozės gydymas | |
GB201608885D0 (en) | Treatment | |
GB201522243D0 (en) | Treatment | |
GB201502137D0 (en) | Treatment | |
IL265259A (en) | Treatment of multiple sclerosis with chs-131 | |
GB201519450D0 (en) | Novel treatment | |
GB201508841D0 (en) | Treatment | |
GB201508385D0 (en) | Metal treatment | |
HK1245157A1 (zh) | 抗菌表面處理 | |
IL272658A (en) | Surface treatment | |
IL269681A (en) | New methods for treating multiple sclerosis | |
RS58951B1 (sr) | Lečenje multiple skleroze | |
EP3294889A4 (en) | Multiple sclerosis treatment | |
GB201503008D0 (en) | Treatment | |
GB201718985D0 (en) | Treatment | |
GB201713650D0 (en) | Treatment | |
GB201617107D0 (en) | Treatment | |
GB201706955D0 (en) | Treatment | |
GB201612260D0 (en) | Treatment | |
GB201612193D0 (en) | Treatment | |
GB201609683D0 (en) | Treatment | |
GB201711677D0 (en) | Combination treatment |